GSK prices €3.5B bond, its largest-ever UK health debt deal
What's the deal? GSK Capital B.V.Dealroom has a profile for this one. Try Dealroom →, the Dutch financing arm of UK pharmaceutical group GSK plc, priced a €3.5 billion four-tranche bond offering on Thursday. BNP Paribas and BofA SecuritiesDealroom has a profile for this one. Try Dealroom → led as global coordinators, joined by HSBCDealroom has a profile for this one. Try Dealroom →, SantanderDealroom has a profile for this one. Try Dealroom →, and Standard Chartered BankDealroom has a profile for this one. Try Dealroom → as active bookrunners.
The breakdown: The deal spans four maturities. An €850 million floating-rate note due 2028 priced at three-month Euribor plus 30bp; a €1 billion tranche due 2030 carries a 3.50% coupon; €850 million of 2034 notes pay 3.875%; and €800 million of 11-year notes due 2037 carry a 4.125% coupon. Settlement is set for September 7, 2026.
Why it stands out: At €3.5 billion, this ranks as the largest post-IPO debt raise on record for a UK health company, topping a sample of 67 comparable deals.
What's the endgame? The multi-tranche structure lets GSK stagger repayment across 2028 to 2037, spreading its refinancing load and locking in fixed rates for the longer maturities.
The signal: Large, investment-grade pharmaceutical issuers continue to tap Europe's bond market at scale, using laddered maturities to manage funding costs across a full decade.
Read more: econostream-media.com
Image credit: zhouxuan12345678
